Shares of Seattle Genetics Inc. leaped 17.6 percent Monday after the firm revealed striking top-line pivotal trial results showing that 75 percent of patients with relapsed-refractory Hodgkin's lymphoma (HL) receiving single agent brentuximab vedotin (SGN-35) achieved an objective response, with a median duration of more than six months. (BioWorld Today) Read More
